

January 30, 2023

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

Dear Sir / Madam,

Please take note that the Board of Directors of PathLabs Unifiers Private Limited ("PUPL") (a Wholly Owned Subsidiary of the Company) in their meeting on January 30, 2023 approved the acquisition of further 10% equity stake in its Subsidiary Company i.e. APRL PathLabs Private Limited ("APRL").

The details as required under Regulation 30 of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

**Rajat Kalra**  
**Company Secretary & Legal Head**

*Encl.: As above*

## Annexure-I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>APRL PathLabs Private Limited (“APRL”) having its registered office at G-32, Race Course Tower, Near Natubhai Circle, Race Course, Vadodara- 390007.</p> <p>At present the Paid-Up Share Capital of APRL is INR 6,33,400/- divided into 63,340 Equity Shares of INR 10/- each.</p> <p><b><u>Turnover of last three Financial Year (FY):</u></b>  FY 2019-20 – INR 19.79 Million  FY 2020-21 – INR 86.98 Million  FY 2021-22 – INR 107.96 Million</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>No, the transaction is not a related party transaction.</p> <p>APRL PathLabs Private Limited is a Subsidiary of PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary of Dr. Lal PathLabs Limited.</p>
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To strengthen the Company’s presence in the state of Gujarat, India.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required

6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	INR. 7.50 Million (approx.)
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Acquisition of further 10% equity stake in APRL by PUPL.  Post this acquisition, total equity stake of PUPL in APRL will increase from 70% to 80%.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	APRL PathLabs Private Limited ("APRL"), incorporated on October 4, 2019 having CIN: U85195GJ2019PTC110176 and registered office at G-32, Race Course Tower, Near Natubhai Circle, Race Course, Vadodara- 390007, is a Company engaged in providing diagnostic services in the state of Gujarat, India.  <b>Turnover:</b> As mentioned in clause 1 above.